ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
128.96
+2.95 (+2.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close126.01
Open126.48
Bid0.00 x 1400
Ask0.00 x 1000
Day's Range126.12 - 129.29
52 Week Range92.56 - 141.86
Volume1,245,585
Avg. Volume1,483,324
Market Cap28.926B
Beta (3Y Monthly)1.75
PE Ratio (TTM)370.57
EPS (TTM)0.35
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est163.00
Trade prices are not sourced from all markets
  • Technician lays out the best bets in biotech
    CNBC Videos7 days ago

    Technician lays out the best bets in biotech

    Technician Chris Verrone looks at the best bets in biotech. With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Steve Grasso and Guy Adami.

  • Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks5 days ago

    Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth

    Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 8 Stocks May Jump on Takeovers as Market Nears Peak
    Investopedia11 days ago

    8 Stocks May Jump on Takeovers as Market Nears Peak

    Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.

  • Business Wire11 days ago

    Alexion to Report First Quarter Results on Thursday, April 25, 2019

    Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019.

  • Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
    Zacks13 days ago

    Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA

    Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).

  • Zacks13 days ago

    S&P Streak Ends as Stocks Step Back

    S&P; Streak Ends as Stocks Step Back

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding ALXN is favorable, with net inflows of $28.04 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Reuters19 days ago

    Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

    Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.

  • Reuters19 days ago

    Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe

    Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.

  • Alexion, other drugmakers pay $123M to settle kickback claims
    American City Business Journals19 days ago

    Alexion, other drugmakers pay $123M to settle kickback claims

    Prosecutors alleged that beginning in 2010, Alexion set up a fund to cover the out-of-pocket costs of its blockbuster drug Soliris.

  • MarketWatch19 days ago

    Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations

    The U.S. Justice Department said Thursday that Jazz Pharmaceuticals PLC , Alexion Pharmaceuticals Inc. and Lundbeck LLC have agreed to pay a combined $122.6 million to settle allegations that they paid kickbacks through co-pay assistance foundations for their own products. The companies violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as conduits, the Justice Department said in a statement. "The Anti-Kickback Statute prohibits a pharmaceutical company from offering or paying, directly or indirectly, any remuneration - which includes money or any other thing of value - to induce Medicare or ChampVA patients to purchase the company's drugs," said the statement. "This prohibition extends to the payment of patients' copay obligations." Jazz and Lundbeck have entered five-year corporate integrity agreements which require that they implement measures, controls and monitoring to promote independence from patient assistance programs. Alexion was exempted from that requirement because it has made sweeping changes following the bad conduct, said the statement. Changes included hiring a new eight-member executive leadership team and changing half of its board. Jazz shares were up 0.5% while Alexion shares were up 0.3%.

  • Achillion Meets Enrollment Target in Kidney Disease Studies
    Zacks19 days ago

    Achillion Meets Enrollment Target in Kidney Disease Studies

    Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.

  • Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy Right Now?
    Insider Monkey25 days ago

    Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy Right Now?

    Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) an attractive stock to buy now? Money managers are betting on the stock. The number of bullish hedge fund bets increased by 4 recently. Our calculations also showed that ALXN isn't among the 30 most popular stocks among hedge funds. ALXN was in 41 hedge funds' portfolios at the end […]

  • Achillion Completes Enrollment in Rare Blood Disorder Study
    Zacks26 days ago

    Achillion Completes Enrollment in Rare Blood Disorder Study

    Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.

  • Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
    Zacks27 days ago

    Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

    Key highlights of the past week are multiple study failures and other pipeline updates.

  • 4 Blockbuster Drug Launches to Watch in 2019
    Motley Foollast month

    4 Blockbuster Drug Launches to Watch in 2019

    These four experimental drugs will reach the market soon, and the companies launching them have little room for error.

  • Most Analysts Are Optimistic on Alexion Pharmaceuticals
    Market Realistlast month

    Most Analysts Are Optimistic on Alexion Pharmaceuticals

    How Major Rare Disease Pharma Stocks Are Positioned in MarchAnalysts’ recommendations and target priceWall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals (ALXN) based on the stock’s closing price on March 21.

  • IBD 50 Growth Stocks To Watch: After Climbing 403% From A 2009 Breakout, Can This Biotech Surge Again?
    Investor's Business Dailylast month

    IBD 50 Growth Stocks To Watch: After Climbing 403% From A 2009 Breakout, Can This Biotech Surge Again?

    Earnings are rising again and revenue growth is accelerating at Alexion Pharmaceuticals, one of the current top growth stocks to watch in the IBD 50.

  • Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
    Business Wirelast month

    Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases

    - Collaboration furthers Alexion’s complement leadership with expansion into peptide therapies -

  • Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
    Business Wirelast month

    Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

    Alexion Pharmaceuticals, Inc. (ALXN) and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn).

  • Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript

    DRNA earnings call for the period ending December 31, 2018.

  • If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today
    Simply Wall St.last month

    If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today

    While not a mind-blowing move, it is good to see that the Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) share price has gained 12% in the last three months. But that doesn't changeRead More...